<DOC>
	<DOCNO>NCT01863459</DOCNO>
	<brief_summary>1 . To evaluate safety , efficacy Lisdexamfetamine dimesylate treatment outpatient DSM-IV ADHD anxiety depressive disorder comorbidity , well evaluate effect quality life . 2 . To evaluate efficacy Lisdexamfetamine dimesylate treatment anxiety depressive disorder commonly occur ADHD . 3 . To examine potential relationship telomere length Adult ADHD comorbidity potential effect treatment response . 4 . To examine potential association specific gene Adult ADHD .</brief_summary>
	<brief_title>Lisdexamfetamine Dimesylate Treatment Adult ADHD With Anxiety Disorder Comorbidity</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<criteria>1 . Outpatient men woman age 18 65 year . 2 . Patients DSMIV diagnosis ADHD accord MINIPlus , ADHDRS score â‰¥ 24 least one follow comorbid psychiatric disorder : SP , PDAG , OCD , GAD , MDD Dysthymia . 3 . Patients qualify comorbid DSMIV major depressive disorder current episode , allow study provide baseline Montgomery Asberg Depression Rating Scale ( MADRS ) score less equal 25 . 4 . The ability comprehend satisfactorily comply protocol requirement . 6 . Written informed consent give prior enter baseline period study . 7 . All woman child bear potential must negative screen visit serum urine pregnancy test use adequate contraception duration study . Medically acceptable form contraception include oral contraceptive , injectable implantable method , intrauterine device properly use barrier contraception . Additionally , use condom suggest adjunct method previously address provide additional protection accidental pregnancy . 8 . Concomitant treatment selective serotonin reuptake inhibitor ( SSRI 's ) , serotonin noradrenaline reuptake inhibitor ( SNRI 's ) , benzodiazepine , betablockers , atypical antipsychotic , antiepileptic allow , provide dose stable 8 week prior study entry . Dose change allow concomitant medication avoid treatment phase study . 1 . Patients currently fulfill criterion lifetime history bipolar disorder , history drug abuse , history schizophrenia psychotic disorder , delirium , dementia amnesic cognitive disorder , current agitate state . 2 . Patients concurrent AXISII , cluster A personality disorder borderline antisocial personality disorder . 3 . Patients significant suicidal ideation ( MADRS item 10 score &gt; 3 ) enact suicidal behaviour within 6 month prior intake exclude study participation refer appropriate clinical intervention . 4 . Patients receive current psychotherapy , include cognitive behavioural therapy either ADHD anxiety mood disorder , within 4 week prior baseline period . 5 . Patients , course study would likely require treatment prohibit concomitant therapy ( please refer Concomitant Medication section ) . 6 . Patients know allergic amphetamine component Lisdexamfetamine dimesylate , know hypersensitivity idiosyncrasy Lisdexamfetamine dimesylate sympathomimetic amine . 7 . Patients current seizure disorder , organic brain disorder history seizure disorder ( except febrile seizure childhood ) . 8 . Patients thyroid pathology , treatment stabilize least 3 month . 9 . MAO inhibitor within 3 week start baseline . 10 . Current use bupropion tricyclic antidepressant , exception clomipramine . 11 . Current use clonidine , modafinil atomoxetine . 12 . Previous intolerance failure respond adequate trial Lisdexamfetamine dimesylate ( define minimum 30mg per day least 4 week ) . 13 . Current use psychostimulant , great 2 fail trial use adequate dos methylphenidatebased amphetamine agent . 14 . Pregnant lactating female sexually active childbearing potential use adequate method birth control . If subject becomes pregnant study discontinue immediately follow appropriately ( minimum , outcome pregnancy determine ) . 15 . Patients history evidence medical condition would expose increase significant adverse event interfere assessment safety efficacy course trial include : advanced arteriosclerosis , symptomatic cardiovascular disease , moderate severe hypertension , preexist cardiac abnormality serious cardiac problem . 16 . Patients history Glaucoma . 17 . Sleep medication study period exclude exception zopiclone overthecounter sleep aid . 18 . Patients use herbal psychoactive treatment , eg ; St.John 's Wort , Valerian , Kava Kava , Chamomile Extract within 14 day prior randomization . 19 . Patients receive electroconvulsive therapy within previous 6 month . 20 . Patients condition therapy investigator 's opinion indicate Lisdexamfetamine dimesylate product label , may pose risk subject interfere study objective . 21 . Patients clinically significant abnormal laboratory ECG finding resolve baseline examination . The exclusion criterion must continue satisfied order patient enter randomization phase end baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>ADHD</keyword>
	<keyword>ADD</keyword>
	<keyword>Anxiety</keyword>
	<keyword>Anxiety Disorders</keyword>
	<keyword>Depression</keyword>
	<keyword>Attention</keyword>
	<keyword>Attention Deficit</keyword>
</DOC>